Investigating treatment response and immune profile in association with pattern identification in NSCLC patients scheduled for immune checkpoint inhibitor monotherapy (HARMONY study): A protocol for a prospective observational study

Korea Institute of Oriental Medicine0 个研究点目标入组 200 人开始时间: 待定最近更新: 2022年5月30日

试验速览

暂无简介。

•1. Patients diagnosed with stage IIIB, IIIC, IV (TNM 8th edition) non-small cell lung cancer
•2. Patients scheduled to be treated for immune checkpoint inhibitor (Pembrolizumab, Atezolizumab) monotherapy for secondary or higher line therapy after platinum-based primary therapy has been failed
•3. Patients over 6 months survival expected
•4. Patients with ECOG scale (ECOG-PS) 0-2
•5. Patients who voluntarily participate to this clinical study with written informed consent

•1. Patients having active brain metastases with clinically significant neurological symptoms or signs
•2. Patients diagnosed with other malignancies within 5 years which may influence non-small cell lung cancer
•3. Patients having autoimmune disease
•4. Pregnant woman or lactating woman
•5. Patients considered to be unsuitable to participate in this study by the investigators

发起方